

References

1. Speed TJ, Parekh V, Coe W, Antoine D. Comorbid chronic pain and opioid use disorder: literature review and potential treatment innovations. *Int Rev Psychiatry*. 2018;30(5):136-146.
2. Ellis MS, Kasper Z, Cicero T. Assessment of chronic pain management in the treatment of opioid use disorder: gaps in care and implications for treatment outcomes. *J Pain*. 2021;22(4):432-439.
3. Voon P, Hayashi K, Milloy M, et al. Pain among high-risk patients on methadone maintenance treatment. *J Pain*. 2015;16(9):887-894.
4. Dennis BB, Bawor M, Paul J, et al. The impact of chronic pain on opioid addiction treatment: a systematic review protocol. *Syst Rev*. 2015;4(1):1-9.
5. Hartz SM, Culverhouse RC, Mintz CM, et al. Association between recent overdose and chronic pain among individuals in treatment for opioid use disorder. *PLOS ONE*. 2022;17(11):e0271379. doi:10.1371/journal.pone.0271379
6. Larson MJ, Paasche-Orlow M, Cheng DM, Lloyd-Travaglini C, Saitz R, Samet JH. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. *Addiction*. 2007;102(5):752-760.
7. Hall OT J; Rood,K; Phan, KL; Clauw, DJ. Central Sensitization In Opioid Use Disorder: A Novel Application of the 2011 American College of Rheumatology Fibromyalgia Survey. Published online 2022.
8. Hall OT, Teater J, Entrup P, et al. Fibromyalgia predicts increased odds of pain-related addiction exacerbation among individuals with pain and opioid use disorder. *Pain*. Published online 2022:10.1097.
9. Shurman J, Koob GF, Gutstein HB. Opioids, Pain, the Brain, and Hyperkatifeia: A Framework for the Rational Use of Opioids for Pain. *Pain Med*. 2010;11(7):1092-1098. doi:10.1111/j.1526-4637.2010.00881.x
10. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociceptive pain: towards an understanding of prevalent pain conditions. *The Lancet*. 2021;397(10289):2098-2110.
11. Harte SE, Harris RE, Clauw DJ. The neurobiology of central sensitization. *J Appl Biobehav Res*. 2018;23(2). doi:10.1111/jabr.12137
12. Elman I, Borsook D. Common brain mechanisms of chronic pain and addiction. *Neuron*. 2016;89(1):11-36.
13. Kreutzwiser D, Tawfic QA. Methadone for Pain Management: A Pharmacotherapeutic Review. *CNS Drugs*. 2020;34(8):827-839. doi:10.1007/s40263-020-00743-3
14. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. *J Support Oncol*. Published online 2012.
15. Kouya PF, Xu XJ. Buprenorphine reduces central sensitization after repetitive C-fiber stimulation in rats. *Neurosci Lett*. 2004;359(1):127-129. doi:10.1016/j.neulet.2004.02.007
16. Trofimovitch D, Baumrucker SJ. Pharmacology update: low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes. *Am J Hosp Palliat Med*. 2019;36(10):907-912.
17. Kohns DJ, Scott R, Castellanos J, Scribner D, Hodges R, Clauw DJ. The impact of nociceptive pain features on the response to physical therapy in patients with primary myofascial pain. *J Back Musculoskelet Rehabil*. 2022;35(5):1143-1151.
18. Nijs J, Lahousse A, Fernández-de-las-Peñas C, et al. Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain

phenotyping using nociplastic pain criteria. *Br J Anaesth*. 2023;130(5):611-621.
doi:10.1016/j.bja.2022.12.013

19. Murphy AE, Minhas D, Clauw DJ, Lee YC. Identifying and Managing Nociplastic Pain in Individuals With Rheumatic Diseases: A Narrative Review. *Arthritis Care Res*. Published online 2023.
20. Nijs J, Malfliet A, Nishigami T. Nociplastic pain and central sensitization in patients with chronic pain conditions: a terminology update for clinicians. *Braz J Phys Ther*. 2023;27(3):100518.
doi:10.1016/j.bjpt.2023.100518
21. Fernández-de-Las-Peñas C, Nijs J, Neblett R, et al. Phenotyping post-COVID pain as a nociceptive, neuropathic, or nociplastic pain condition. *Biomedicines*. 2022;10(10):2562.
22. Hall OT, Entrup P, King A, et al. Central sensitization in alcohol use disorder: correlates of pain, addiction and health-related quality of life. *J Addict Dis*. 2023;0(0):1-12. doi:10.1080/10550887.2023.2237396
23. Larach DB, Sahara MJ, As-Sanie S, et al. Patient factors associated with opioid consumption in the month following major surgery. *Ann Surg*. 2021;273(3):507.
24. Brummett CM, Urquhart AG, Hassett AL, et al. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. *Arthritis Rheumatol*. 2015;67(5):1386-1394.
25. Janda AM, As-Sanie S, Rajala B, et al. Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. *Anesthesiology*. 2015;122(5):1103-1111.
26. Goesling J, Henry MJ, Moser SE, et al. Symptoms of depression are associated with opioid use regardless of pain severity and physical functioning among treatment-seeking patients with chronic pain. *J Pain*. 2015;16(9):844-851.
27. Hooten WM, Brummett CM, Sullivan MD, et al. A conceptual framework for understanding unintended prolonged opioid use. In: *Mayo Clinic Proceedings*. Vol 92. Elsevier; 2017:1822-1830.
28. As-Sanie S, Till SR, Mowers EL, et al. Opioid prescribing patterns, patient use, and postoperative pain after benign hysterectomy. *Obstet Gynecol*. 2017;130(6):1261.
29. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. *BMC Musculoskelet Disord*. 2004;5:1-7.
30. Schrepf A, Harper DE, Harte SE, et al. Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. *Pain*. 2016;157(10):2217.
31. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and Characteristics of Chronic Pain Among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities. *JAMA*. 2003;289(18):2370-2378. doi:10.1001/jama.289.18.2370
32. Trafton JA, Oliva EM, Horst DA, Minkel JD, Humphreys K. Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment. *Drug Alcohol Depend*. 2004;73(1):23-31.
33. Jamison RN, Kauffman J, Katz NP. Characteristics of Methadone Maintenance Patients with Chronic Pain. *J Pain Symptom Manage*. 2000;19(1):53-62. doi:10.1016/S0885-3924(99)00144-X
34. Barry DT, Bernard MJ, Beitel M, Moore BA, Kerns RD, Schottenfeld RS. Counselors' Experiences Treating Methadone-maintained Patients with Chronic Pain: A Needs Assessment Study. *J Addict Med*. 2008;2(2):108. doi:10.1097/ADM.0b013e31815ec240

35. Blanco C, Wall MM, Okuda M, Wang S, Iza M, Olfson M. Pain as a predictor of opioid use disorder in a nationally representative sample. *Am J Psychiatry*. 2016;173(12):1189-1195.
36. Weiss RD, Potter JS, Griffin ML, et al. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. *J Subst Abuse Treat*. 2014;47(2):140-145.
37. Bonar EE, Ilgen MA, Walton M, Bohnert AS. Associations among pain, non-medical prescription opioid use, and drug overdose history. *Am J Addict*. 2014;23(1):41-47.
38. Fernandez AC, Bush C, Bonar EE, Blow FC, Walton MA, Bohnert AA. Alcohol and drug overdose and the influence of pain conditions in an addiction treatment sample. *J Addict Med*. 2019;13(1):61.
39. Britton PC, Wines Jr JD, Conner KR. Non-fatal overdose in the 12 months following treatment for substance use disorders. *Drug Alcohol Depend*. 2010;107(1):51-55.
40. Loeser J. Terminology | International Association for the Study of Pain. International Association for the Study of Pain (IASP). Published 2021. Accessed December 27, 2022. <https://www.iasp-pain.org/resources/terminology/>
41. Kosek E, Clauw D, Nijs J, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. *PAIN*. 2021;162(11):2629. doi:10.1097/j.pain.0000000000002324
42. Larkin TE, Kaplan CM, Schrepf A, et al. Altered network architecture of functional brain communities in chronic nociplastic pain. *Neuroimage*. 2021;226:117504.
43. Kratz AL, Whibley D, Alschuler KN, et al. Characterizing chronic pain phenotypes in multiple sclerosis: a nationwide survey study. *Pain*. 2021;162(5):1426.
44. Schrepf A, Maixner W, Fillingim R, et al. The Chronic Overlapping Pain Condition Screener. *J Pain*. Published online 2023.
45. Hall OT, Teater J, Rood KM, Phan KL, Clauw DJ. Central sensitization in opioid use disorder: a novel application of the American College of Rheumatology Fibromyalgia Survey Criteria. *Pain Rep*. 2022;7(4).
46. Hall OT, Teater J, Entrup P, et al. Fibromyalgia predicts increased odds of pain-related addiction exacerbation among individuals with pain and opioid use disorder. *Pain*. Published online 2022:10.1097.
47. Aoyagi K, He J, Nicol AL, et al. A subgroup of chronic low back pain patients with central sensitization. *Clin J Pain*. 2019;35(11):869-879.
48. Basu N, Kaplan CM, Ichesco E, et al. Neurobiologic features of fibromyalgia are also present among rheumatoid arthritis patients. *Arthritis Rheumatol*. 2018;70(7):1000-1007.
49. Brummett CM, Janda AM, Schueller CM, et al. Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower-extremity joint arthroplasty: a prospective, observational cohort study. *Anesthesiology*. 2013;119(6):1434-1443.
50. Janda AM, As-Sanie S, Rajala B, et al. Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. *Anesthesiology*. 2015;122(5):1103-1111.
51. Clauw DJ, Hassett AL. The role of centralised pain in osteoarthritis. *Clin Exp Rheumatol*. 2017;35(Suppl 107):79-84.
52. Neville SJ, Clauw AD, Moser SE, et al. Association Between the 2011 Fibromyalgia Survey Criteria and Multisite Pain Sensitivity in Knee Osteoarthritis. *Clin J Pain*. 2018;34(10):909-917. doi:10.1097/AJP.0000000000000619

53. Nicol A, Arnold P, Clauw D. (321) Fibromyalgia-ness in persistent low back pain after lumbar spine surgery: a preliminary investigation. *J Pain*. 2017;18(4):S55.
54. Harte SE, Harris RE, Clauw DJ. The neurobiology of central sensitization. *J Appl Biobehav Res*. 2018;23(2):e12137.
55. Hatfield E, Phillips K, Swidan S, Ashman L. Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. *J Am Dent Assoc*. 2020;151(12):891-902.e1. doi:10.1016/j.adaj.2020.08.019
56. Karnik NS, Marsden J, McCluskey C, et al. The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study. *Addiction*. 2022;117(9):2438-2447. doi:10.1111/add.15875
57. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59(20):22-33.
58. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2005;113(1-2):9-19.
59. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*. 2008;9(2):105-121.
60. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2003;106(3):337-345.
61. doverty m. Hyperalgesic responses in methadone maintenance patients. *Pain*. Published online February 1, 2001. doi:0.1016/s0304-3959(00)00391-2
62. Koppert W, Ihmsen H, Körber N, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. *Pain*. 2005;118(1):15-22. doi:10.1016/j.pain.2005.06.030
63. Wandner LD, Domenichiello AF, Beierlein J, et al. NIH's Helping to End Addiction Long-term SM Initiative (NIH HEAL Initiative) Clinical Pain Management Common Data Element Program. *J Pain*. 2022;23(3):370-378.
64. Ballantyne JC, Fishman SM, Rathmell JP. *Bonica's Management of Pain*. Lippincott Williams & Wilkins; 2018.
65. Benzon H, Raja SN, Fishman SM, Liu SS, Cohen SP. *Essentials of Pain Medicine E-Book*. Elsevier Health Sciences; 2017.
66. (IASP) IA for the S of P. IASP Terminology UR -: <https://www.iasp-pain.org/terminology?navItemNumber=576#Centralsensitization>.
67. Harte S, Clauw D, Clauw A, Scott R, Moser S, Brummett C. The 2011 Fibromyalgia (FM) Survey Criteria Are a Surrogate Measure of Pain Centralization: Abstract Number: 2290. *Arthritis Rheumatol*. 2015;67:2764-2765.
68. Freynhagen R, Baron R, Gockel U, Tölle TR. Pain DETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin*. 2006;22(10):1911-1920.
69. Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS®-29 v2. 0 profile physical and mental health summary scores. *Qual Life Res*. 2018;27:1885-1891.

70. Cheng ST, Chen PP, Chow YF, et al. The Pain Catastrophizing Scale—short form: psychometric properties and threshold for identifying high-risk individuals. *Int Psychogeriatr*. 2019;31(11):1665-1674.
71. PhenX Toolkit: Protocols. Accessed September 3, 2023. <https://www.phenxtoolkit.org/protocols/view/860801?origin=browse>
72. Boyett B, Wiest K, McLeod LD, et al. Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS. *Drug Alcohol Depend*. 2021;229(Pt B):109057. doi:10.1016/j.drugalcdep.2021.109057
73. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. *Pain*. 2006;123(3):231-243. doi:10.1016/j.pain.2006.01.041
74. Geber C, Klein T, Azad S, et al. Test–retest and interobserver reliability of quantitative sensory testing according to the protocol of the German Research Network on Neuropathic Pain (DFNS): a multi-centre study. *PAIN®*. 2011;152(3):548-556.
75. Schmidt H, Drusko A, Renz M, et al. Application of the IASP grading system for ‘nociceptive pain’ in chronic pain conditions: A field study. *medRxiv*. Published online 2022:2022.12.06.22283114.
76. Digital Algometer - AlgoMed | Medoc. QST devices | Medoc - Advanced Medical Systems. Accessed September 20, 2023. <https://www.medoc-web.com/algomed>
77. Hassett AL, Williams DA, Harris RE, et al. An Interventional Response Phenotyping Study in Chronic Low Back Pain: Protocol for a Mechanistic Randomized Controlled Trial. *Pain Med*. 2023;24(Supplement_1):S126-S138. doi:10.1093/pm/pnad005
78. Huhn A, Strain E, Bigelow G, Smith M, Edwards R, Tompkins D. (289) Conditioned Pain Modulation in Buprenorphine-Maintained Patients with Opioid Use Disorder. *J Pain*. 2019;20(4, Supplement):S46-S47. doi:10.1016/j.jpain.2019.01.211
79. Harper DE, Ichesco E, Schrepf A, et al. Resting functional connectivity of the periaqueductal gray is associated with normal inhibition and pathological facilitation in conditioned pain modulation. *J Pain*. 2018;19(6):635. e1-635. e15.
80. Schoen CJ, Ablin JN, Ichesco E, et al. A novel paradigm to evaluate conditioned pain modulation in fibromyalgia. *J Pain Res*. Published online 2016:711-719.
81. Kmiecik MJ, Tu FF, Clauw DJ, Hellman KM. Multimodal hypersensitivity derived from quantitative sensory testing predicts pelvic pain outcome: an observational cohort study. *Pain*. 2023;164(9):2070-2083.
82. Kruger G, Harte SE, Ichesco E, et al. Multimodal automated quantitative sensory testing system for pain research. Published online 2011.
83. Harte SE, Mitra M, Ichesco EA, et al. Development and validation of a pressure-type automated quantitative sensory testing system for point-of-care pain assessment. *Med Biol Eng Comput*. 2013;51(6):633-644.
84. Harte SE, Ichesco E, Hampson JP, et al. Pharmacologic attenuation of cross-modal sensory augmentation within the chronic pain insula. *Pain*. 2016;157(9):1933.
85. Kmiecik MJ, Tu FF, Siltan RL, et al. Cortical mechanisms of visual hypersensitivity in women at risk for chronic pelvic pain. *medRxiv*. Published online 2021.

86. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. *J Rheumatol*. 2011;38(6):1113-1122.
87. Moreton BJ, Tew V, das Nair R, Wheeler M, Walsh DA, Lincoln NB. Pain phenotype in patients with knee osteoarthritis: classification and measurement properties of painDETECT and self-report Leeds assessment of neuropathic symptoms and signs scale in a cross-sectional study. *Arthritis Care Res*. 2015;67(4):519-528.
88. Freynhagen R, Tölle TR, Gockel U, Baron R. The painDETECT project—far more than a screening tool on neuropathic pain. *Curr Med Res Opin*. 2016;32(6):1033-1057.
89. Gauffin J, Hankama T, Kautiainen H, Hannonen P, Haanpää M. Neuropathic pain and use of Pain DETECT in patients with fibromyalgia: a cohort study. *BMC Neurol*. 2013;13:1-6.
90. Hochman JR, Davis AM, Elkayam J, Gagliese L, Hawker GA. Neuropathic pain symptoms on the modified painDETECT correlate with signs of central sensitization in knee osteoarthritis. *Osteoarthritis Cartilage*. 2013;21(9):1236-1242.
91. Amtmann D, Cook KF, Jensen MP, et al. Development of a PROMIS item bank to measure pain interference. *Pain*. 2010;150(1):173-182.
92. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med*. 2009;24(6):733-738. doi:10.1007/s11606-009-0981-1
93. Ferguson L, Scheman J. Patient global impression of change scores within the context of a chronic pain rehabilitation program. *J Pain*. 2009;10(4):S73.
94. Rolstad S, Adler J, Rydén A. Response burden and questionnaire length: is shorter better? A review and meta-analysis. *Value Health*. 2011;14(8):1101-1108.
95. Atkinson TM, Schwartz CE, Goldstein L, et al. Perceptions of response burden associated with completion of patient-reported outcome assessments in oncology. *Value Health*. 2019;22(2):225-230.
96. Kutch JJ, Ichesco E, Hampson JP, et al. Brain signature and functional impact of centralized pain: a multidisciplinary approach to the study of chronic pelvic pain (MAPP) network study. *PAIN*. 2017;158(10):1979. doi:10.1097/j.pain.0000000000001001
97. Back Pain Consortium (BACPAC) Research Program. NIH HEAL Initiative. Published August 18, 2019. Accessed October 30, 2022. <https://heal.nih.gov/research/clinical-research/back-pain>
98. Hall OT J; Rood,K; Phan, KL; Clauw, DJ. Central Sensitization In Opioid Use Disorder: A Novel Application of the 2011 American College of Rheumatology Fibromyalgia Survey. Published online 2022.
99. Greco CM, Wasan AD, Schneider MJ, et al. Biobehavioral Assessments in BACPAC: Recommendations, Rationale, and Methods. *Pain Med*. 2023;24(Supplement_1):S61-S70. doi:10.1093/pm/pnac175
100. Harte SE, Schrepf A, Gallop R, et al. Quantitative Assessment of Non-Pelvic Pressure Pain Sensitivity in Urological Chronic Pelvic Pain Syndrome: A MAPP Research Network Study. *Pain*. 2019;160(6):1270-1280. doi:10.1097/j.pain.0000000000001505
101. Lai HH, Naliboff B, Liu AB, et al. The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations. *Contemp Clin Trials*. 2018;74:76-87. doi:10.1016/j.cct.2018.09.010

102. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019;95:103208.
103. Metricwire Inc. | Real-World Data | Real-Life Impact. Metricwire Inc. Accessed September 3, 2023. <https://metricwire.com/>
104. ASAM. [cited 2024 Feb 2]. What is the Definition of Addiction? Available from: <https://www.asam.org/quality-care/definition-of-addiction>
105. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain.* 2020 Sep 1;161(9):1976-82.
106. Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-enhanced management of fibromyalgia: a randomized controlled trial. *PAIN®.* 2010 Dec 1;151(3):694-702.
107. Geraghty AW, Maund E, Newell D, Santer M, Everitt H, Price C, Pincus T, Moore M, Little P, West R, Stuart B. Self-management for chronic widespread pain including fibromyalgia: a systematic review and meta-analysis. *PLoS One.* 2021 Jul 16;16(7):e0254642.
108. The Curbsiders - An Internal Medicine Podcast [Internet]. 2022 [cited 2024 Feb 2]. # 8 Back to Basics: A Stigma-Free History - The Curbsiders. Available from: <https://thecurbsiders.com/addiction-medicine-podcast/8-back-to-basics-a-stigma-free-history>
109. Hall OT, Rausch J, Entrup P, Lagisetty P, Bryan C, Black L, Moreno J, Gorka S, Phan KL, Clauw DJ. Nociceptive Pain and Pain-Motivated Drinking in Alcohol Use Disorder. *The Journal of Pain.* 2024 Jan 12.
110. Hall OT, Entrup P, King A, Vilensky M, Bryan CJ, Teater J, Niedermier J, Kaplan CM, Turner JA, Gorka S, Harte SE. Central sensitization in alcohol use disorder: correlates of pain, addiction and health-related quality of life. *Journal of Addictive Diseases.* 2023 Jul 14:1-2.